Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cellular immune responses in multiple sclerosis patients treated with interferon-beta.

Literature DB >> 23379429

Cellular immune responses in multiple sclerosis patients treated with interferon-beta.

M F Bustamante¹, J Rio, Z Castro, A Sánchez, X Montalban, M Comabella.

Abstract

We investigated cellular immune responses at baseline in peripheral blood mononuclear cells (PBMC) of patients with multiple sclerosis (MS) treated with interferon (IFN)-β and classified into responders and non-responders according to clinical response criteria. Levels for IFN-γ, interleukin (IL)-17A, IL-17F, IL-10 and IL-4 were determined in activated PBMC of 10 responders, 10 non-responders and 10 healthy controls by cytometric bead arrays. Cytokine levels in cell culture supernatants were similar between responders and non-responders, and comparable to those obtained in healthy controls. These findings do not support differential cellular immune responses in PBMC at baseline between IFN-β responders and non-responders.

Entities: Disease Gene Species

Mesh：

Substances：
Cytokines
Interferon-beta

Year: 2013 PMID： 23379429 PMCID： PMC3569530 DOI： 10.1111/cei.12016

Source DB: PubMed Journal: Clin Exp Immunol ISSN： 0009-9104 Impact factor: 4.330

13 in total

1. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.

Authors: S E Bushnell; Z Zhao; C C Stebbins; D Cadavid; A M Buko; E T Whalley; J A Davis; E M Versage; J R Richert; R C Axtell; L Steinman; R Medori
Journal: Neurology Date: 2012-05-09 Impact factor: 9.910

2. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis.

Authors: M Comabella; J D Lünemann; J Río; A Sánchez; C López; E Julià; M Fernández; L Nonell; M Camiña-Tato; F Deisenhammer; E Caballero; M T Tortola; M Prinz; X Montalban; R Martin
Journal: Brain Date: 2009-12 Impact factor: 13.501

3. New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors: C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal: Ann Neurol Date: 1983-03 Impact factor: 10.422

4. Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming.

Authors: Agnes Le Bon; Vanessa Durand; Elisabeth Kamphuis; Clare Thompson; Silvia Bulfone-Paus; Cornelia Rossmann; Ulrich Kalinke; David F Tough
Journal: J Immunol Date: 2006-04-15 Impact factor: 5.422

5. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors:
Journal: Lancet Date: 1998-11-07 Impact factor: 79.321

6. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors:
Journal: Neurology Date: 1993-04 Impact factor: 9.910

7. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.

Authors: Jordi Río; Carlos Nos; Mar Tintoré; Cecilia Borrás; Ingrid Galán; Manuel Comabella; Xavier Montalban
Journal: Ann Neurol Date: 2002-10 Impact factor: 10.422

8. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors: L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal: Ann Neurol Date: 1996-03 Impact factor: 10.422